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Trial enrichment using gut microbiota derived biomarkers by high-risk individuals can
improve the feasibility of randomized controlled trials for prevention of Clostridioides difficile
infection (CDI). Here, we report in a prospective observational cohort study the incidence of
CDI and assess potential clinical characteristics and biomarkers to predict CDI in 1,007
patients ≥ 50 years receiving newly initiated antibiotic treatment with penicillins plus a beta-
lactamase inhibitor, 3rd/4th generation cephalosporins, carbapenems, fluoroquinolones or
clindamycin from 34 European hospitals. The estimated 90-day cumulative incidences of a
first CDI episode is 1.9% (95% CI 1.1-3.0). Carbapenem treatment (Hazard Ratio (95% CI):
5.3 (1.7-16.6)), toxigenic C. difficile rectal carriage (10.3 (3.2-33.1)), high intestinal abundance
of Enterococcus spp. relative to Ruminococcus spp. (5.4 (2.1-18.7)), and low Shannon alpha
diversity index as determined by 16 S rRNA gene profiling (9.7 (3.2-29.7)), but not nor-
malized urinary 3-indoxyl sulfate levels, predicts an increased CDI risk.
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C lostridioides difficile infections (CDI) are considered theleading cause of infectious healthcare-related diarrheaworldwide and substantial costs have been attributed to
its management1–3. Different medical interventions, including
vaccines, probiotics, and agents neutralizing antibiotic residuals
in the colon, are being developed to prevent CDI4–7. These
interventions, however, require data from pivotal trials demon-
strating clinical efficacy prior to approval by regulatory autho-
rities. Given the relatively low incidence of CDI per individual
patient in target populations, trials require large numbers of
patients to demonstrate efficacy of a preventive measure. For
example, a trial assessing the efficacy of probiotics for the pre-
vention of CDI included 2981 patients, assuming a 12-week
incidence of 4%. As the incidence of CDI in the placebo group
was only 1.2%, the trial failed to demonstrate efficacy, and would
have required a more than threefold larger sample size to reach
adequate power for a 50% reduction of CDI8. The assumed
incidence of the primary outcome is critical for successful
execution of a trial and should be assessed in depth. Furthermore,
the sample size can be reduced by enrichment of the RCT
population with patients at a particularly high risk of CDI. Pre-
vious attempts to specify such a population identified advanced
age, comorbidities, specific high-risk antibiotics (clindamycin,
cephalosporins, fluoroquinolones, co-amoxiclav, carbapenems,
and trimethoprim/sulfonamides), and previous colonization with
C. difficile as potentially important predictive factors9–11. More
recent findings suggest that the composition of the gut microbiota
and their associated metabolites play an important role in the
pathogenesis of CDI12,13. Therefore, further assessment of these
potential biomarkers is warranted.
Here, we demonstrate that the 90-day incidence of CDI and
antibiotic-associated diarrhea (AAD) in patients ≥ 50 years of age
treated with predefined broad-spectrum antibiotic classes is 1.9%
(95% CI: 1.1–3.0) and 14.1% (95% CI: 12.0–16.4), and that car-
bapenem treatment, toxigenic C. difficile carriage, and the com-
position and diversity of the gut microbiota predict CDI but
not AAD.
Results
A total of 1007 evaluable participants were enrolled (Fig. 1).
Median age was 70 years (IQR: 62–79) and 592 participants
(58.8%) were male (Table 1). Of 172 (17.1%) subjects who did not
complete follow-up, 86 died after a median of 20 (IQR: 8–40)
days and 86 withdrew their consent or were lost-to-follow-up
after a median of 5 (IQR: 3–11) days.
Antibiotic treatment at day 1 and overall is provided in Table 2.
The first dose of one of the five antibiotic classes was given after a
median of 1 (IQR: 0–2) hospitalization day. Most participants
(93%) received only one of the five antibiotic classes on day 1,
most frequently a penicillin with a beta-lactamase inhibitor, fol-
lowed by a third or fourth generation cephalosporin (Table 2).
Apart from these five classes, 19% of patients received other
additional antibiotics on day 1.
In total, 135 participants reported 176 AAD episodes, of which
114 episodes in 100 participants occurred within 28 days. The
cumulative incidence of AAD within 28 and 90 days was 10.5%
(95% CI: 8.6–12.5) and 14.6% (95% CI: 12.4–17.0), respectively.
In 48 AAD episodes, no fecal sample was obtained for diagnosis
of CDI, mainly because episodes were reported too late. Ten other
subjects had fecal samples collected that were not correctly tested.
The remaining 118 were tested according to the ESCMID
guidelines, of which 5 were tested in the hospital laboratory only.
Overall, 17 CDI episodes were detected in 15 subjects. Of these,
nine first episodes occurred within 28 days. The number of
subjects and CDI episodes per country and site are provided in
Supplementary Table 2. The median time to the first CDI episode
was 18 days (IQR: 4–38; range: 1–78). The imputation model
deviated from the planned analysis due to unforeseen imputation
model overfit and indications for missing not at random (see
Supplementary methods). After correction, the imputation model
estimated that, among the non-tested AAD episodes, three CDI
episodes were missed, of which two within 28 days. The estimated
cumulative incidence of CDI, therefore, was 1.1% (95% CI:
0.6–2.1) within 28 days and 1.9% (95% CI: 1.1–3.0) within
90 days (Table 3).
Participants receiving carbapenems at day 1 had a higher inci-
dence of CDI over the 90-days period than other patients (Table 3).
Baseline toxigenic C. difficile carriage results were available in 983
(97.6%) participants, of which 35 were positive. The incidence of
CDI was more than tenfold higher in participants with a positive
baseline toxigenic C. difficile polymerase chain reaction (PCR) for
the follow-up period of 28 and 90 days (Table 3). Time to first CDI
was considerably shorter for participants with baseline toxigenic
C. difficile carriage: 2 days (IQR: 1–3) vs. 30 days (IQR: 16–44) for
those developing CDI but without baseline toxigenic C. difficile
carriage (see Supplementary Table 4).
Baseline N3-IS levels were available for 938 (93.1%) partici-
pants. The distribution of N3-IS levels at baseline was comparable
for patients developing or not developing AAD or CDI (Sup-
plementary Table 3). None of the participants had a low baseline
N3-IS level. No CDI episodes were identified in 28 participants
with intermediate N3-IS levels. The AUC of baseline N3-IS for
CDI within 90 days was 0.441 (95% CI: 0.323–0.559). No dis-
criminative cut-off value for baseline N3-IS level for prediction of
CDI was identified.
Day-6 N3-IS levels were available in 806 subjects of which 3
had CDI and 13 had AAD without known CDI status prior to the
day-6 visit. As 6 subjects withdrew from the study at the day-6
visit, there were 784 subjects for this analysis. Day-6 N3-IS levels
were lower in patients developing CDI compared to those not
developing CDI (Supplementary Table 3). In 199 (25.4%) subjects
with intermediate day-6 N3-IS levels, the cumulative incidence of
CDI at day 90 was 4.1% (95% CI: 1.9–7.6), compared to 0.7%
(95% CI: 0.2–2.0) in subjects with high day-6 N3-IS levels (SDHR:
5.8 (95% CI: 1.6–21.4)).
Baseline 16S rRNA gene profiling analysis results were avail-
able in 945 (93.8%) participants. A detailed description of the
metagenomic analyses, including determination of alpha and beta
diversity indices and LEfSe results, is reported in Berkell et al.14.
For baseline alpha diversity, participants with a CDI episode had
a median Shannon index of 2.19 (IQR: 1.87–3.37) and Inverse
Simpson index of 5.53 (IQR: 3.12–17.33), while participants
without a reported CDI episode had a median Shannon index of
3.38 (IQR: 2.91–3.76) and Inverse Simpson index of 13.87 (IQR:
8.74–21.26). Both indices were strongly predictive for CDI
(Table 3) and moderately for AAD (Table 4).
The LEfSe analysis revealed two OTUs associated with CDI and
17 with no CDI (Supplementary Table 3 in Berkell et al.14), of
which two and eight, respectively, had mean relative abundance of
at least 0.5% and were selected for modeling. Based on model AICs
and confirmation in the validation dataset, the best OTU-ratio
model consisted of the relative abundance of Enterococcus (OTU1)
divided by the relative abundance of Ruminococcus (OTU31), as in
Table 3 (see Supplementary Table 5 for alternative models). Overall,
171 subjects (16.9%) were above the optimal breakpoint and had a
predicted 90-day risk of CDI of 5.7%. For the OTU-abundance
model, Enterococcus (OTU1) and Alistipes (OTU68) was selected as
the best model (Table 3, Supplementary Table 6). 181 subjects
(18.0%) had relative abundance of Enterococcus (OTU1) ≥ 0.087%
and Alistipes (OTU68) < 0.087% and had a predicted 90-day CDI
risk of 5.8%. The SDHR of the selected OTU models was similar to
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the RR observed in the validation dataset: RR 4.6 (95% CI: 1.4–28.8)
for the ratio of OTU1/OTU31 and RR 6.2 (95% CI: 2.0–34.8) for
the relative abundance of OTU1 ≥ 0.087% and OTU68 < 0.087%
(Supplementary Tables 5 and 6). Most but not all of the alternative
OTU models were confirmed in the validation. For CDI within
28 days, predictive performance of 16S rRNA gene sequencing data
could not be estimated due to the low number of CDI episodes
within 28 days.
Different sensitivity analyses confirmed that rectal carriage of
toxigenic C. difficile and the selected OTU models were predictive
for CDI (Supplementary Tables 7–12). However, in the subset of
countries with high testing rates, relative abundance of
Porphyromonas (OTU69) turned out to be more predictive as
compared to OTUs selected in the main analysis. Carbapenem
use at baseline was confirmed in some sensitivity analyses, but
lost statistical significance in the subset of countries with high
testing rates. Further exploration of the data revealed that CDI
testing was correctly performed in 81% of AAD episodes in
patients with baseline carbapenem use, compared to 65% of other
AAD episodes. Due to the low number of CDI episodes observed,
the original plan to perform multivariable analysis for CDI pre-
diction was abandoned.
The incidence of AAD was increased threefold in subjects














AB ongoing for >6 hours: 543
Social or logistical condition: 283
Wrong AB class: 85
Not hospitalized: 72
Diarrhoea or CDI at inclusion: 71
(Anticipated) ICU admission: 52
Has stoma: 31
Deprived of liberty: 12
MD prescribed probiotics: 11
Legal protection: 11
Previously included subject: 5
Age < 50: 14
Unspecified: 121
Refuses rectal swabs: 60
Patient condition: 47
Procedures to burdensome: 46
Logistical reason: 17
Language barrier: 9
Participates in other study: 3
Other: 4
Diarrhoea or CDI at inclusion: 31
AB ongoing for >6 hours: 23
Wrong AB class: 13
Social or logistical condition: 10
Age < 50: 5
MD prescribed probiotics: 2
Legal protection: 2
Not hospitalized: 1
(Anticipated) ICU admission: 1
Previously included subject: 1
Has stoma: 1
Died within 90 days: 86
Could not be contacted: 22
Unspecified: 19
Reconsidered participation: 16
Refused study procedures: 13
Patient condition: 10
Withdrawn by investigator: 6
Fig. 1 Inclusion flowchart. *Based on 28 hospitals that provided screening data. Hospitals were requested to complete on the screening log for all screened
patients up to March 23, 2017, and all eligible patients for the entire study period. Of the enrolled patients, 897 (89.1%) were enrolled in hospitals that
provided screening data. **Subjects who signed informed consent but met one of the exclusion criteria at baseline. This includes 33 subjects from one side
that applied an early consent procedure for subjects at high risk of receiving antibiotics in the near future. Abbreviations: AB antibiotics, CDI C. difficile
infection, ICU intensive care unit, MD medical doctor.
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receiving carbapenems at baseline (Table 4). Other antibiotic
classes, history of CDI, toxigenic C. difficile carriage and N3-IS
levels were not associated with an increased AAD incidence. The
LEfSe analysis revealed 6 OTUs associated with CDI and 16 with
no CDI (Supplementary Table 4 in Berkell et al.14), of which four
and nine, respectively, had mean relative abundance of at least
0.5% and were selected for modeling. The ratio of the respective
relative abundances of uncultured Lachnospiraceae (OTU21) over
Blautia (OTU648) was selected as the best OTU ratio model
(Table 4, see Supplementary Table 13 for AIC values). Subjects
with this ratio ≥ 6 had a cumulative incidence of AAD within
90 days of 20.0% compared to 12.3% in the other subjects. The C-
statistic of this model was 0.555, particularly due to a low sen-
sitivity (Table 4 footnote). For the OTU-abundance model, low
abundances of Porphyromonas (OTU69) and Blautia (OTU648)
and high abundance of Lachnospiraceae (OTU21) best predicted
an increased AAD risk, with similar predicted risks and C-statistic
as compared to the OTU ratio model (Table 4, Supplementary
Table 13). The complete case analysis confirmed the association
of carbapenems and OTU models with AAD (Supplementary
Tables 14 and 15).
Discussion
In this study of adults aged ≥ 50 years receiving broad-spectrum
systemic antibiotic treatment during hospitalization, we observed
a cumulative CDI incidence of 1.1% (95% CI: 0.6–2.1) within
28 days and 1.9% (95% CI: 1.1–3.0) within 90 days of antibiotic
treatment initiation. Carbapenem prescription, rectal carriage of
toxigenic C. difficile at baseline, a low alpha diversity of the
intestinal microbiome, as well as a high relative abundance of
Enterococcus (OTU1) and low relative abundance of Rumino-
coccus (OTU31) or Alistipes (OTU68) predicted an increased risk
of CDI. Urinary N3-IS level at baseline was not associated with
occurrence of CDI. AAD could not be predicted reliably with any
of the studied parameters. The involvement of different infectious
and non-infectious causes of AAD may hamper accurate
biomarker-based prediction of AAD.
Although all evaluated antibiotic classes have been associated
with CDI, in our study, only patients treated with carbapenems
had a threefold increased risk of AAD and an almost fivefold
increased risk of CDI within 90 days as compared to patients not
receiving carbapenems at baseline. The higher incidence in
patients receiving carbapenems may be due to the broader anti-
microbial activity spectrum resulting in more disruption of the
intestinal microbiota, or to differences in baseline risk factors in
patients receiving carbapenems compared to those receiving other
antibiotics. Independent of the mechanism, enrichment of a trial
population with patients receiving carbapenems is likely to
increase the incidence of CDI and hence make a trial more effi-
cient. The expected efficiency gain will be driven by the pro-
portion of patients receiving carbapenems, which was relatively
low in our study, but varied substantially among hospitals. Few
patients received clindamycin and CDI was observed in none,
prohibiting incidence estimation for this antibiotic. Less than 2%
of our population had a history of CDI, a risk factor for which we
could not determine the incidence of CDI, due to the absence of
outcomes in this small subgroup, even though CDI history has
previously been found to predict a high CDI risk15.
We studied three distinct biomarker types. Previous studies
have found associations between urinary N3-IS levels and the
microbiota composition. In particular, the relative abundance of
bacteria from the class Clostridia was positively associated with
N3-IS, whereas Bacilli were negatively associated with N3-IS16,17.
As Clostridia have been associated with a decreased and Bacilli
with an increased CDI risk, we hypothesized that patients with a
low N3-IS level would be at an increased risk of CDI18–21.
However, in our study baseline N3-IS level was not predictive.
Yet, there was an association between low day-6 N3-IS level and
an increased CDI incidence afterwards, confirming the direction
of the hypothesized association. Altogether, we conclude that N3-
IS is very unlikely to be a relevant baseline predictor of CDI risk
in this patient population, but when measured after several days
of antibiotic treatment it may predict the subsequent risk of CDI.
Toxigenic C. difficile carriage at baseline was detected in 3.6% of
participants. In previous studies, the prevalence of toxigenic
C. difficile carriage was very heterogeneous with a pooled pre-
valence of 8.1% (95% CI: 5.7–11.1%)11. The low observed carriage
prevalence may be due to a potentially lower sensitivity of rectal
swabs compared to stool samples for detection of toxigenic
C. difficile carriage. PCR testing based on swabs dipped in stool
samples of CDI patients has yielded high detection rates, but this
may be different for detection of colonization22. On the other
Table 1 Baseline characteristics.
Baseline variable Total population
(n= 1007)
Age (median [IQR]) 70.0 [61.5, 79.0]
Male gender (%) 592 (58.8)
Charlson comorbidity index (median [IQR]) 5.1 [3.8, 6.8]
Karnofski score (median [IQR]) 80 [70, 90]
Cardiovascular disease (%) 321 (31.9)
Hematological/oncological disease (%) 340 (33.8)
Diabetes mellitus (%) 281 (27.9)
COPD (%) 160 (15.9)
Gastrointestinal disease (%) 156 (15.5)
Moderate to severe chronic kidney
disease (%)
132 (13.1)
Connective tissue disease (%) 54 (5.4)
AIDS (%) 11 (1.1)
Has history of CDI (%) 14 (1.5)
Years since last CDI episode
(median [IQR])
0.8 [0.3, 1.1]
Used systemic antibiotics in past
3 months (%)
405 (42.0)
Used immunosuppressants in past
3 months (%)
232 (23.2)
Used proton pump inhibitors in past
3 months (%)
497 (50.9)
Hospitalized in past 12 months (%)
Not hospitalized 463 (46.8)
Once 261 (26.4)
Twice 102 (10.3)
Three or more times 163 (16.5)
Received outpatient care in past month (%) 556 (55.5)
Received tube feeding during current
admission prior to inclusion (%)
8 (0.8)
ICU admission in past 3 months (%) 33 (3.3)
Indication for antibiotic treatmenta
Respiratory tract infection 340 (33.8%)
Urinary tract infection 171 (17.0%)
Abdominal infection 157 (15.6%)
Prophylactic treatment 90 (8.9%)
Febrile neutropenia 85 (8.4%)
Skin and soft tissue infection 66 (6.6%)
Other indications 122 (12.1%)
aTotals add up to >100% because some patients had more than one indication. Other
indications include, bacteriuria (1), Bartonellosis (1), blood stream infection (15), cervical lymph
node tuberculosis (1), central nervous system infection (7), endocarditis (13), infection with
unknown focus (33), Lyme’s disease (2), ocular infection (4), orchitis (1), osteoarticular
infection (32), pericarditis (2), prosthesis infection (3), surgical site infection (5), Trauma (1),
Vasculitis (2).
Abbreviations: AIDS acquired immunodeficiency syndrome, CDI Clostridioides difficile infection,
COPD chronic obstructive pulmonary disease, ICU intensive care unit, IQR interquartile range.
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Table 2 Antibiotic treatment at baseline and during follow-up.
Variable N (%) D1 N (%) any time DOT
One antibiotic classa 939 (93.2%) 607 (60.3%)
Two antibiotic classesa 66 (6.6%) 319 (31.7%)
Three+ antibiotic classesa 2 (0.2%) 81 (8.0%)
One antibiotic classb 758 (75.3%) 412 (40.9%)
Two antibiotic classesb 236 (23.4%) 363 (36.0%)
Three+ antibiotic classesb 13 (1.3%) 232 (23.0%)
Penicillin with beta-lactamase inhibitor 409 (40.6%) 530 (52.6%) 8 (5–12)
Third or fourth generation cephalosporin 394 (39.1%) 457 (45.4%) 7 (4–9)
Fluoroquinolone 181 (18.0%) 326 (32.4%) 9 (6–15)
Carbapenem 64 (6.4%) 143 (14.2%) 8 (5–14)
Clindamycin 29 (2.9%) 45 (4.5%) 8 (5–13)
Other antibiotic classes 193 (19.2%) 407 (40.4%) 9 (5–17)
Any antibiotic 1007 (100.0%) 1007 (100.0%) 11 (7–22)
aOut of the five antibiotic classes given, not including other classes.
bIncluding other antibiotic classes.
Abbreviations: D1 day one of antibiotic treatment, DOT days on treatment given as Median (interquartile range); combination treatment is counted as one DOT.
Table 3 Cumulative incidence of CDI within 28 and 90 days.
Subgroup N Events Incidence SDHR
CDI within 28 days
Total population 1007 11.0 1.1% (0.6–2.1)
Penicillin+ BLI 409 4.4 1.1% (0.4–2.7) 1.0 (0.3–3.6)
Third/fourth gen cephalosporin 394 3.5 0.9% (0.2–2.5) 0.7 (0.2–2.8)
Fluoroquinolone 181 1.6 0.9% (0.1–4.1) 0.7 (0.1–5.1)
Carbapenem 64 2.5 4.0% (0.8–11.8) 4.2 (0.9–19.3)
Clindamycin 29 0.3 – –
History of CDI 31 0.5 – –
No history of CDI 976 10.6 1.1% (0.6–2.1) –
Toxigenic C. difficile carriage (GeneXpert, Cepheid) 45 4.6 10.6% (3.2–23.2) 16.2 (4.3–60.8)
No toxigenic C. difficile carriage 962 6.5 0.7% (0.3–1.6) –
Intermediate N3-IS level (−8≤ log2(N3-IS)≤ 2.5) 38 0.2 – –
High N3-IS level (log2(N3-IS) > 2.5) 969 10.8 1.2% (0.6–2.1) –
Shannon index≤ 2.586 164 7.2 4.6% (1.9–9.1) 10.2 (2.3–44.4)
Shannon index > 2.586 843 3.8 0.5% (0.1–1.4) –
Inverse Simpson index≤ 7.674 220 7.2 3.5% (1.5–6.9) 7.4 (1.6–33.0)
Inverse Simpson index > 7.674 787 3.8 0.5% (0.1–1.5) –
CDI within 90 days
Total population 1007 18.0 1.9% (1.1–3.0)
Penicillin+ BLI 409 5.4 1.4% (0.5–3.1) 0.6 (0.2–1.8)
Third/fourth gen cephalosporin 394 7.1 1.9% (0.8–3.9) 1.0 (0.4–2.8)
Fluoroquinolone 181 2.7 1.6% (0.3–4.9) 0.8 (0.2–3.3)
Carbapenem 64 5.1 8.3% (2.7–17.7) 5.7 (1.9–17.4)
Clindamycin 29 0.3 – –
History of CDI 31 0.8 – –
No history of CDI 976 17.1 1.9% (1.1–3.0) –
Toxigenic C. difficile carriage (GeneXpert, Cepheid) 45 4.9 11.4% (3.4–24.8) 8.6 (2.7–27.5)
No toxigenic C. difficile carriage 962 13.1 1.5% (0.8–2.5) –
Intermediate N3-IS level (−8≤ log2(N3-IS)≤ 2.5) 38 0.3 – –
High N3-IS level (log2(N3-IS) > 2.5) 969 17.7 1.9% (1.1–3.1) –
Shannon index≤ 2.586 164 11.6 7.5% (3.7–13.0) 9.7 (3.2–29.7)
Shannon index > 2.586 843 6.4 0.8% (0.3–1.8) –
Inverse Simpson index≤ 7.674 220 11.6 5.7% (2.9–9.8) 6.9 (2.3–21.3)
Inverse Simpson index > 7.674 787 6.4 0.9% (0.3–2.0) –
Ratio OTU1/OTU31≥ 8.5a 171 11.5 5.7% (1.8–13.5) 5.4 (2.1–18.7)
Ratio OTU1/OTU31 < 8.5 836 6.4 1.1% (0.4–2.4) –
OTU1≥ 0.087% and OTU68 < 0.087%b 181 11.3 5.8% (2.3–11.8) 5.4 (2.0–19.5)
OTU1 < 0.087% OR OTU68≥ 0.087% 826 6.7 1.1% (0.4–2.3) –
Based on the competing events model using multiple imputed data. The number of events is averaged over the imputation datasets and can therefore have decimals. Cumulative incidence was calculated
using competing events analysis. Abbreviations: BLI beta-lactamase inhibitor, CDI Clostridioides difficile infection, CI confidence interval, N3-IS normalized 3-indoxyl sulfate level in urine, OTU1 Enterococcus,
OTU31 Ruminococcus, OTU68 Alistipes, SDHR subdistribution hazard ratio. Bold text denotes statistical significance. a,b Bias-adjusted incidences and SDHRs are provided.
aThe bias-adjusted sensitivity, specificity and C-statistic were 51.2%, 83.7%, and 0.675, respectively.
bThe bias-adjusted sensitivity, specificity and C-statistic were 54.4%, 82.8% and 0.686, respectively.
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hand, the relative risk of toxigenic C. difficile carriage for CDI is
high compared to previous studies in which relative risks between
2.5 and 10 have been observed11. The very short time to CDI
occurrence in participants colonized with C. difficile was surpris-
ing. A recent study among hospitalized medical patients also using
PCR testing on rectal swabs for detection of toxigenic C. difficile
found a similar carriage rate of 3.4% and a relative risk for CDI
among carriers of 16.6 (95% CI: 4.0–69.1), but no difference in
time to occurrence of CDI (median [range] 23 [4–30] days for
carriers vs. 11 [4–30] days for noncarriers)23. The low prevalence
of C. difficile carriage would make this biomarker very inefficient
for enrichment of prevention trials, as about 30 patients would
need to be screened to enroll one high risk patient. Moreover,
rapid point-of-care testing must be available with affordable cost.
Concerning the 16S rRNA analysis, Enterococcus (OTU1),
Ruminococcus (OTU31), or Alistipes (OTU68) were most pre-
dictive of the risk of CDI. Participants with more or equal than
8.5 times higher relative abundance of Enterococcus compared to
Ruminococcus had a fivefold higher risk to develop CDI. Patients
with high relative abundance of Enterococcus and low relative
abundance of Alistipes also had an increased risk of approxi-
mately 5 times. Several alternative models with similar perfor-
mance were identified. There is large uncertainty around these
estimates, with high risk of false positive findings, due to the low
number of CDI episodes and substantial expected bias that nee-
ded to be corrected for. Therefore, we validated our findings in an
independent dataset and selected from the best performing
models those that were confirmed in the validation dataset.
High abundance of Enterococcaceae spp. has previously been
associated with CDI risk18. Ruminococcus spp. are a member of
the class Clostridia, which have repeatedly been associated with a
decreased risk of CDI18–21. Alistipes spp. are a member of the
phylum Bacteroidetes which have also been associated with CDI
in two of these studies18,19. We fitted two different types
of models, which had comparable performance, but may have
different applications in practice. The identified ratio of
Table 4 Cumulative incidence of AAD within 28 and 90 days.
Subgroup N Events Incidence SDHR
AAD within 28 days
Total population 1007 101.7 10.5% (8.7–12.6)
Penicillin+ BLI 409 45.5 11.6% (8.6–15.0) 1.2 (0.8-1.8)
Third/fourth gen cephalosporin 394 29.6 7.8% (5.3–10.8) 0.6 (0.4–1.0)
Fluoroquinolone 181 18.6 10.7% (6.6–15.9) 1.0 (0.6–1.7)
Carbapenem 64 15.6 25.0% (14.9–36.4) 2.8 (1.7–4.9)
Clindamycin 29 2.0 7.6% (1.3–21.8) 0.7 (0.2–2.6)
History of CDI 31 3.8 13.0% (2.5–32.1) 1.2 (0.3–4.6)
No history of CDI 976 97.9 10.4% (8.5–12.5) –
Toxigenic C. difficile carriage (GeneXpert, Cepheid) 45 7.8 18.1% (7.9–31.4) 1.9 (0.9-4.0)
No toxigenic C. difficile carriage 962 93.9 10.2% (8.3–12.2) –
Intermediate N3-IS level (−8≤ log2(N3-IS)≤ 2.5) 38 2.8 7.5% (1.5–20.1) 0.7 (0.2-2.7)
High N3-IS level (log2(N3-IS) > 2.5) 969 98.9 10.6% (8.7–12.7) –
Shannon index≤ 3.155 399 49.4 12.8% (9.6–16.5) 1.5 (1.0-2.2)
Shannon index > 3.155 608 52.4 9.0% (6.8–11.5) –
Inverse Simpson index≤ 14.339 529 59.2 11.6% (8.9–14.6) 1.3 (0.8-1.9)
Inverse Simpson index > 14.339 478 42.5 9.3% (6.8–12.2) –
AAD within 90 days
Total population 1007 135.0 14.1% (12.0–16.4)
Penicillin+ BLI 409 51.0 13.1% (9.9–16.6) 0.9 (0.6–1.3)
Third/fourth gen cephalosporin 394 47.0 12.6% (9.4–16.1) 0.8 (0.6–1.1)
Fluoroquinolone 181 25.0 14.6% (9.8–20.3) 1.0 (0.7–1.6)
Carbapenem 64 21.0 33.8% (22.3–45.7) 3.0 (1.9–4.7)
Clindamycin 29 3.0 11.4% (2.8–26.8) 0.8 (0.2–2.3)
History of CDI 31 3.9 13.4% (2.6–33.0) 0.9 (0.2–3.6)
No history of CDI 976 131.1 14.1% (11.9–16.5) –
Toxigenic C. difficile carriage (GeneXpert, Cepheid) 45 8.3 19% (8.6–32.5) 1.5 (0.7–3.1)
No toxigenic C. difficile carriage 962 126.7 13.9% (11.7–16.2) –
Intermediate N3-IS level (−8≤ log2(N3-IS)≤ 2.5) 38 4.1 11.0% (3.0–24.7) 0.8 (0.2–2.3)
High N3-IS level (log2(N3-IS) > 2.5) 969 130.9 14.2% (12.0–16.6) –
Shannon index≤ 3.155 399 67.2 17.7% (13.9–21.8) 1.5 (1.1–2.2)
Shannon index > 3.155 608 67.8 11.7% (9.2–14.5) –
Inverse Simpson index≤ 14.339 529 80.1 15.9% (12.8–19.3) 1.3 (0.9–1.9)
Inverse Simpson index > 14.339 478 54.9 12.1% (9.3–15.4) –
Ratio OTU21/OTU648≥ 6§ 227 51.0 20.0% (14.7–25.8) 1.7 (1.3–2.4)
Ratio OTU21/OTU648 < 6 780 84.0 12.3% (9.9–15.2) –
At least two of OTU69 < 0.140% or OTU21≥ 0.013% or OTU648 <
0.006%a
448 87.2 18.4% (14.4–22.8) 1.8 (1.4–2.4)
Less than two of OTU69 < 0.140% or OTU21≥ 0.013% or OTU648 <
0.006%
559 47.8 10.6% (8.2–13.4) –
Based on the competing events model using multiple imputed data. The number of events is averaged over the imputation datasets and can therefore have decimals. Cumulative incidence was calculated
using competing events analysis. Abbreviations: AAD antibiotic associated diarrhea, BLI beta-lactamase inhibitor, CDI Clostridioides difficile infection, CI confidence interval, N3-IS normalized 3-indoxyl
sulfate level in urine, OTU21 uncultured Lachnospiraceae, OTU69 Porphyromonas, OTU648 Blautia, SDHR subdistribution hazard ratio. Bold text denotes statistical significance. §,†Bias-adjusted incidences
and SDHR are provided. §The bias-adjusted sensitivity, specificity and C-statistic were 32.1%, 79.0%, and 0.555, respectively.
aThe bias-adjusted sensitivity, specificity and C-statistic were 58.2%, 57.8% and 0.580, respectively.
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Enterococcus/Ruminococcus could be translated into a duplex
quantitative PCR that could serve as a rapid point-of-care
screening test to identify patients at high risk of CDI and to
enrich trial populations. The design of such a test would require
further testing and optimization and independent confirmation of
the predictive performance. Unfortunately this could not be
performed in the current study due to lack of leftover material.
The OTU-coefficients model may be more useful if relative
abundances are generated, such as with 16S rRNA gene analysis
or similar techniques. Recent advances in high-throughput
sequencing, such as nanopore technology may allow the point-
of-care application of this model or rapid estimation of alpha
diversity in the future. At present, however, the costs associated
with such analyses would probably not outweigh the benefits of
more accurate risk prediction.
Several limitations of the study have to be discussed. First, we
lacked a CDI test result in one third of AAD episodes, mostly due
to delayed reporting of diarrhea by the participant, especially after
hospital discharge. The apparent difference in testing between
antibiotic groups may have influenced the association with car-
bapenem use and lack of association with other antibiotic classes.
If CDI causes more severe diarrhea symptoms compared to non-
CDI AAD, patients with CDI may have reported diarrhea more
frequently, thus fewer CDI episodes might be missing. To our
knowledge, however, there is no published data to support this
and we did not collect data on diarrhea severity. Apparently, the
collection of information through a daily paper diary was insuf-
ficient to keep participants aware of the requirement to report
diarrheal episodes. For future studies, more active follow-up
procedures should be considered, such as a smartphone app,
repeated text messages, or regular telephone calls. We mitigated
the problem of missing samples by performing multiple impu-
tation and we performed different sensitivity analyses to test the
robustness of the results, which yielded similar results. Second,
the low number of CDI episodes in our study precluded multi-
variable analysis. Hence, whether carbapenem use, C. difficile
carriage, and the selected OTUs are independent predictors
remains to be determined. Third, 9% of included participants
were lost for other reasons than death, of which most withdrawals
occurred around day 6. The collection of another rectal swab and
urine sample during the second visit apparently decreased the
willingness of participants to continue study participation. We
solved this analytically by applying a survival model, which allows
censoring of follow-up times. However, this model assumes
uninformative censoring, which cannot be substantiated
with data.
Due to the low incidence of CDI, a trial aiming to prevent CDI
in this target population will require a substantial number of
subjects. For example, with a baseline 28-day CDI incidence of
1.2% and a relative reduction of 50%, 5205 patients per arm are
needed to achieve 90% power at a two-sided significance level of
0.05. Using a risk factor (e.g., a biomarker) to enrich the trial with
high-risk patients reduces the number of patients for randomi-
zation and follow-up. At the same time, the number of patients
that must be screened for the risk factor will most likely increase.
The ideal risk factor has a fairly high prevalence in the population
(e.g., 20 or 30%) and is strongly associated with the outcome of
interest. The OTU-based risk prediction of CDI meets these
criteria. Yet, the feasibility of such risk prediction also depends on
the ease and cost of screening. A biomarker is more expensive to
measure than comorbidities, hence even if the biomarker would
constitute a stronger risk factor, it may be less efficient to use.
Potentially, a multivariable approach using patient history,
demographics, antibiotic exposure and clinically available
laboratory test results would be as good as the biomarkers tested
in our study. Alternatively, the biomarkers could be of added
value in patients with an intermediate predicted risk based on
clinically available predictors. All of this could not be tested in
this study due to the low number of CDI episodes.
In conclusion, the 28 and 90-day incidences of CDI in patients
≥50 years receiving broad-spectrum antibiotics during hospitali-
zation were 1.14% and 1.89%, respectively. Carbapenem treat-
ment, C. difficile carriage, and high relative abundance of
Enterococcus spp. vs. low relative abundance of Ruminococcus
spp. or Alistipes spp. at baseline predicted occurrence of CDI, the
latter being confirmed in an independent validation dataset with
similar relative risks despite being from a different design and
setting.
Methods
Study design. The “AssessmeNT of the Incidence of C. difficile Infections in
hospitalized Patients on Antibiotic TrEatment” (ANTICIPATE) study was an
international multicenter prospective observational cohort study in 34 hospitals (21
university and 13 nonuniversity hospitals) from France, Germany, Greece, the
Netherlands, Romania and Spain. Patients were recruited from September 2016
through October 2017. The study protocol was approved by a central ethics review
board in each country and/or the local institutional review boards of each hospital,
in accordance with the local regulations (Supplementary methods: Ethics com-
mittees). The study was registered at ClinicalTrials.gov: NCT02896244.
Eligibility and recruitment. Pharmacy registries or admission lists of hospitalized
patients were screened for eligibility during office hours. Patients were eligible if
they met the following inclusion criteria: (1) hospitalization at the time of
enrollment, (2) age ≥ 50 years, (3) initiation of treatment less than 6 h before
enrollment or scheduled treatment within the next 72 h of intravenous or oral
treatment with an intended duration ≥5 days (≥1 day for clindamycin) with at least
one of the following antibiotic classes: third or fourth generation cephalosporins,
fluoroquinolones, penicillins with beta-lactamase inhibitors, clindamycin, or car-
bapenems. Exclusion criteria were: (1) ongoing antibiotic treatment with one of the
above classes initiated >6 h before inclusion into the study, (2) ICU admission at
the time of inclusion or anticipated ICU admission within 48 h, (3) suspected or
diagnosed CDI, ongoing treatment for CDI, or diarrhea at the time of inclusion, (4)
stoma, (5) previous inclusion into the study, (6) ongoing probiotic treatment for
prevention of CDI, (7) social or logistical condition which in the opinion of the
investigator might interfere with the conduct of the study, (8) subject to legal
protection, and (9) deprived of liberty by judicial or administrative decision.
Written informed consent was obtained from all participants prior to any study
related procedures.
Outcome definitions. The primary endpoint was CDI within 28 days after
initiation of antibiotic treatment. An episode of CDI was defined as a clinical
picture compatible with CDI and microbiological evidence of free toxins and the
presence of C. difficile in stools, using one of the two algorithms recommended in
the 2016 European Society of Clinical Microbiology and Infectious Diseases
(ESCMID) guideline, without reasonable evidence of another cause of diarrhea, or
pseudomembranous colitis as diagnosed during endoscopy, after colectomy or on
autopsy24. Diarrhea was defined as loose stools, i.e., taking the shape of the
receptacle, corresponding to Bristol stool chart types 5–7, and a stool frequency of
at least three in 24 consecutive hours. Secondary endpoints included incidence of
CDI within 90 days and incidence of AAD within 28 and 90 days.
Data and samples. During the enrollment visit, a urine sample for normalized
3-indoxyl sulfate (N3-IS, expressed as nmol 3-IS/µmol creatinine), a rectal swab for
16S rRNA gene profiling, and a rectal swab for C. difficile carriage detection by PCR
(Cepheid GeneXpert) were collected. At study day 6 ± 1 (or day 3 or 4 in case of
early discharge), another urine sample for N3-IS measurement and rectal swab for
16S rRNA profiling were collected. Data on baseline demographics and comor-
bidities, use of antibiotics and laxatives, as well as diarrhea episodes during hos-
pitalization where retrieved from medical records. In addition, participants were
asked to complete a diary on a daily basis assessing presence of diarrhea, use of
antibiotics, and of laxatives throughout the 90-day follow-up period. At the end-of-
study visit after study day 90 (either a phone call or a bed-side visit), the diary was
collected and a final inquiry made about potentially missed diarrheal episodes. If
participants reported diarrhea during the 90-day follow-up period, an additional
fresh fecal sample was collected and tested for CDI in a national central laboratory.
The hospitals’ routine fecal collectors were used for episodes occurring during
hospitalization and participants received a stool collection system for episodes
occurring after discharge. See supplementary methods for detailed description of
sample collection and processing.
Sample size calculation. The primary aim of this study was to estimate the
incidence of CDI, which would be the main determinant of sample size calculations
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of any RCT targeting the prevention of CDI in this at-risk population. The sample
size was chosen such that the impact of randomly over- or underestimating the
incidence would be acceptably low. Assuming an event rate of approximately 2% in
the total included population, 839 participants would be needed to accurately
determine the event rate. Assuming an event rate of 5% in one of the subgroups,
335 participants would be needed in that subgroup to accurately determine the
event rate in the high-risk group. If one third of participants were part of such a
high-risk population, this would require a total study population of 1005 patients.
Therefore, we aimed to include 1000 participants into the study. This sample size
was deemed sufficient to perform a robust sample size calculation for an RCT.
Data analysis. Data were analyzed in R version 3.5.1 (2018-07-02)25. Baseline
characteristics, antibiotic use, and sample collection data are given for the total
population as proportions, mean (SD), or median (IQR), as appropriate.
Missing CDI test results from the central laboratory were complemented with
the local laboratory results, if tested according to one of the ESCMID algorithms.
For other missing data, we used the mice package for multiple imputation with 100
imputed datasets (see Supplementary methods). We used Rubin’s rule to derive
confidence intervals.
16S rRNA gene sequencing was performed as described in Berkell et al.14.
Potential predictive biomarkers that emerged from the linear discriminant analysis
effect size (LEfSe) model performed for CDI vs. no CDI and AAD (including CDI)
vs. no AAD at the level of the operational taxonomic unit (OTU) were utilized for
further analysis here. OTUs were defined by a cut-off of 97% similarity of the reads
which is supposed to resemble species boundaries, although imperfect26.
To calculate the incidences of CDI and AAD at day 28 and day 90, cumulative
incidences were estimated from the imputed data using the cumulative incidence
function with death as a competing event (cmprsk package version 2.2–7)27. This
method takes loss to follow-up and competing events (death) into account.
Stratified cumulative incidences were estimated per subgroup and were compared
using subdistribution hazard ratios (SDHR) from the competing events model. The
SDHR is calculated as the ratio of the subdistribution hazard function, which is
defined as the instantaneous rate or events of a certain type in subjects who have
not yet experienced that event28 and can be interpreted as a relative risk if the
incidence is low. Predefined subgroups were antibiotic class at baseline, history of
CDI, baseline toxigenic C. difficile carriage, and low, intermediate and high N3-IS
levels at baseline.
Stratified incidences for baseline N3-IS levels were first analyzed using
previously published breakpoints and categorized as low (log2(N3-IS) <−8),
intermediate (−8 ≤ log2(N3-IS) ≤ 2.5), or high (log2(N3-IS) > 2.5)16. Next, we
calculated the area under the curve (AUC) of the receiver operating characteristic
(ROC; pROC package version 1.13.0) and determined the optimal breakpoint based
on the Youden index (29; OptimalCutpoints package version 1.1–3), assuming a
lower value would be associated with a higher CDI risk. We also performed an
unplanned analysis of CDI incidences at day 90 stratified for day-6 N3-IS levels
(using the previously published breakpoints) in patients with no CDI prior to the
day-6 visit and with day-6 N3-IS results available.
The microbiome-based risk strata were not prespecified. We defined low and
high alpha diversity based on the Shannon index and Inverse Simpson index, for
which we used the Youden index for dichotomization29. From the OTUs associated
with the studied outcome identified by LEfSe14, we further selected those with
mean relative abundance of at least 0.5%. Based on these OTUs we defined two
kinds of biomarkers. The first group of biomarkers were the ratio of the respective
relative abundances of one positively and one negatively associated OTU (termed
OTU ratio). For the negatively associated OTU, counts of zero were set to 0.5 to
avoid division by zero. We used the Youden index for dichotomization29. The
dichotomized OTU ratios were tested in the competing events model and ranked
by Akaikes Information Criterion (AIC). The second group of biomarkers were
OTU relative abundances, dichotomized based on the Youden index. These were
tested in the competing event model as separate coefficients in a step-wise forward
selection procedure based on the AIC using a selection threshold of −2 points. For
both model selection approaches, we performed bootstrap cross-validation to
determine the bias-corrected incidences, SDHR, sensitivity, specificity and C-
statistic. The OTU model results for CDI were subsequently externally validated
using data from a previously published nested case–control study18. In short, of 599
hospitalized adult patients prospectively enrolled in this Canadian study and
followed until 60 days after discharge, 31 developed CDI, of which fecal samples
collected prior to the onset of CDI were available in 25 patients. These were
matched to 25 non-CDI patients on sex, age (±5 years) and date of hospitalization
(±2 months). Raw reads were retrieved from the corresponding author and
processed to align with our analysis as described by Berkell et al.14. One CDI case
with only 32 remaining reads was excluded from the analysis. For calculation of
incidences and relative risks (RR), we applied weights in accordance to the
sampling fraction of cases and controls and performed bootstrapping to derive 95%
confidence intervals. Among the candidate OTU models derived from the
ANTICIPATE data and that also predicted CDI in the validation dataset, the
models with the lowest AIC value were selected as best predictive model.
The following sensitivity analyses were performed for CDI: (1) using non-
imputed data assuming that missing CDI test results were negative (i.e., cumulative
incidence of observed CDI); (2) complete case analysis, excluding participants with
AAD but missing CDI test results; (3) restricted to countries with at least 75% of
AAD episodes tested for CDI.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
16S rRNA and shotgun metagenomic sequence data generated and analyzed in this study
have been deposited in the NCBI Sequence Read Archive with the accession code
PRJNA685914. Human reads were identified and removed prior to shotgun
metagenomics data upload. All other data generated in this study are available from the
corresponding author upon reasonable requests; access to clinical data is restricted as the
informed consent provided does not allow for open publication of these data. Raw data
from Vincent et al.18 utilized as a validation cohort in this study was kindly provided by
Prof. Amee Mangees (University of Brittish Columbia, Vancouver, Canada).
Code availability
An example dataset and analysis code is provided as supplementary information. Full
analysis code can be requested from the corresponding author.
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